Fate Therapeutics (NQ: FATE )
5.390 +0.160 (+3.06%) Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
All News about Fate Therapeutics
Cathie Wood Scoops Up Over $20M Worth Of Fate Therapeutics Shares, Dumps More Twitter Stock
August 12, 2022
Cathie Wood-led Ark Investment Management has bought 628,060 shares of clinical-stage biopharmaceutical company Fate Therapeutics Inc. (NASDAQ: FATE) through two of the firm’s exchange-traded funds...
Fate Therapeutics Initiated With Hold Rating - Read Why
July 28, 2022
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...
Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in...
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch
February 08, 2022
Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century...
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
December 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following